Sanofi and Orano Med, a subsidiary of the Orano Group, have announced a strategic partnership to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. The collaboration will leverage the expertise and pipeline of Orano Med, a pioneer in targeted alpha therapies, to create a new entity focused on the discovery, design, and clinical development of lead-212 based RLTs.   Targeted alpha therapy is a promising approach that combines the precision of biological...